Login to Your Account



Financings Roundup

Akebia's $41M Cash Infusion Boosts Anemia Drug Work

By Catherine Shaffer
Staff Writer

Wednesday, June 5, 2013
A bit more than a year after handing in positive results in a Phase II study for AKB-6548 in chronic kidney disease (CKD), Akebia Therapeutics Inc., of Cincinnati, secured a $41 million Series C financing to fund ongoing development of the drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription